|
Market Closed -
Nasdaq
16:00:00 2025-05-20 EDT
|
5-day change | 1st Jan Change | ||
| 9.600 USD | -1.13% |
|
-.--% | - |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index | CI |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index | CI |
| Market Cap | 97.22M 84.78M 80.05M 72.69M 136M 9.33B 137M 959M 370M 4.74B 365M 357M 15.26B | P/E 2023 |
-4.07x | P/E 2024 | -3.15x |
|---|---|---|---|---|---|
| Enterprise Value | 142M 124M 117M 106M 198M 13.6B 199M 1.4B 539M 6.91B 532M 520M 22.24B | EV / Sales 2023 |
2.86x | EV / Sales 2024 | 1.43x |
| Free-Float |
6.21% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -1.13% |
| 3 years | 4.81 |  | 31.5 |
| 5 years | 4.81 | | 64.5 |
| 10 years | 4.81 | | 450 |
| Manager | Title | Age | Since |
|---|---|---|---|
Evan Loh
CEO | Chief Executive Officer | 67 | 2025-05-20 |
| Chief Tech/Sci/R&D Officer | - | 2019-12-31 | |
Jonathan Neely
IRC | Investor Relations Contact | - | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Evan Loh
BRD | Director/Board Member | 67 | 2025-05-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/21/25 | Issuer sale | Chief Financial Officer | 82,491 | 0.8204% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -.--% | -.--% | -53.62% | 97.22M | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | +0.07% | +2.93% | +23.53% | +35.41% | 360.18B | |
| Weighted average by Cap. | +0.23% | +3.09% | +35.15% | +61.76% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 70.99M 61.9M 58.45M 53.08M 99.44M 6.81B 99.86M 700M 270M 3.46B 267M 261M 11.14B | 78.23M 68.21M 64.41M 58.49M 110M 7.51B 110M 772M 298M 3.82B 294M 287M 12.28B |
| Net income | -35.48M -30.94M -29.22M -26.53M -49.71M -3.4B -49.91M -350M -135M -1.73B -133M -130M -5.57B | -21.54M -18.78M -17.74M -16.11M -30.18M -2.07B -30.3M -212M -81.99M -1.05B -80.92M -79.12M -3.38B |
| Net Debt | 58.06M 50.63M 47.81M 43.41M 81.34M 5.57B 81.68M 573M 221M 2.83B 218M 213M 9.11B | 44.48M 38.78M 36.62M 33.25M 62.3M 4.27B 62.56M 439M 169M 2.17B 167M 163M 6.98B |
Employees
128
Sector
Pharmaceuticals
- Stock Market
- Stocks
- OPTN Stock
Select your edition
All financial news and data tailored to specific country editions
